CD34 and cancer: While the administration of 75 μg filgrastim 16–18 h prior to apheresis did not mobilize CD34+ cells, rather indicating an optimized condition for ex vivo induction of DCs from monocytes that led to an increase in the ratio of patients who could acquire immunity against cancer-associated antigens (Table 1).